venBio Global Strategic Fund IV, L.P.
CIK: 0001862109
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Attovia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Direct2.3M shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Direct822K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Direct665.1K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Purchase(P)Direct382.4K shares at avg. $17.00$6.5M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Conversion(C) | 2,311,870 | - | $0 | Direct |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Conversion(C) | 821,998 | - | $0 | Direct |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Conversion(C) | 665,147 | - | $0 | Direct |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Purchase(P) | 382,352 | $17.00 | $6,499,984 | Direct |
1-4 of 4 transactions
About venBio Global Strategic Fund IV, L.P.
venBio Global Strategic Fund IV, L.P. (SEC CIK 0001862109) files insider reports with the SEC as 10% Owner of Attovia Therapeutics, Inc. (ATTO).
Signal8 holds 2 ownership filings by venBio Global Strategic Fund IV, L.P. (1 Form 3, 1 Form 4), filed between Aug 4, 2026 and Aug 10, 2026. Those filings report 4 transactions, the latest on Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on venBio Global Strategic Fund IV, L.P.'s filings is in SAN FRANCISCO, CA.
Recent filings by venBio Global Strategic Fund IV, L.P.
Other insiders filing for Attovia Therapeutics, Inc. (ATTO)
- Fu Tao, President and CEO
- Chan Steven, Chief Financial Officer
- WALSH COLIN, Director
- GOLDMAN SACHS GROUP INC, Officer
- Deep Track Biotechnology Master Fund, Ltd., 10% Owner
- Redmile Group, LLC, 10% Owner